Theravance Biopharma (NASDAQ:TBPH) Major Shareholder Eli Samaha Sells 273,871 Shares of Stock

Theravance Biopharma, Inc. (NASDAQ:TBPH) major shareholder Eli Samaha sold 273,871 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $17.23, for a total transaction of $4,718,797.33. Following the sale, the insider owned 9,237,279 shares in the company, valued at approximately $159,158,317.17. The trade was a 2.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Eli Samaha also recently made the following trade(s):

• On Wednesday, July 1st, Eli Samaha sold 37,799 shares of Theravance Biopharma stock. The shares were sold at an average price of $17.00, for a total transaction of $642,583.00.
• On Tuesday, June 30th, Eli Samaha sold 25,027 shares of Theravance Biopharma stock. The stock was sold at an average price of $17.13, for a total transaction of $428,712.51.

Theravance Biopharma Price Performance

Shares of NASDAQ TBPH opened at $16.98 on Thursday. The firm has a fifty day moving average price of $16.56 and a 200-day moving average price of $17.29. The stock has a market cap of $875.37 million, a PE ratio of 7.72 and a beta of 0.17. Theravance Biopharma, Inc. has a 1 year low of $10.82 and a 1 year high of $21.03.

Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings data on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) EPS for the quarter. Theravance Biopharma had a net margin of 104.34% and a return on equity of 18.84%. The firm had revenue of $17.70 million for the quarter. On average, research analysts expect that Theravance Biopharma, Inc. will post 1.54 EPS for the current year.

Institutional Investors Weigh In On Theravance Biopharma

Large investors have recently bought and sold shares of the business. Quarry LP bought a new position in Theravance Biopharma during the third quarter valued at $26,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Theravance Biopharma by 26.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock worth $46,000 after buying an additional 515 shares during the last quarter. Caitong International Asset Management Co. Ltd increased its holdings in shares of Theravance Biopharma by 107.4% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 1,411 shares during the last quarter. CIBC Private Wealth Group LLC raised its position in shares of Theravance Biopharma by 20,269.6% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock valued at $68,000 after buying an additional 4,662 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its position in shares of Theravance Biopharma by 18.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock valued at $55,000 after buying an additional 781 shares in the last quarter. Institutional investors own 99.10% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. Wall Street Zen lowered Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. TD Cowen lifted their target price on Theravance Biopharma from $13.00 to $15.00 and gave the company a “hold” rating in a research note on Monday, March 23rd. Weiss Ratings cut Theravance Biopharma from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, May 27th. BTIG Research downgraded Theravance Biopharma from a “buy” rating to a “neutral” rating in a research note on Monday. Finally, Oppenheimer lowered shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating in a report on Thursday, March 5th. One equities research analyst has rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat.com, Theravance Biopharma has a consensus rating of “Hold” and a consensus price target of $21.40.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.